To investigate whether further FAT1 depletion could boost CPI‐613's antitumor activity, we treated SCC1 tongue tumor‐bearing NSG mice with CPI‐613 and LNP‐sgFAT1, either alone or in combination, following the treatment schedule outlined in Figure 6H. The gene discussed is FAT1; the disease is tongue neoplasm.